ZyVersa Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . ZyVersa Therapeutics
ZVSA Stock   0.24  0.01  4.35%   
ZyVersa Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing ZyVersa Therapeutics' valuation are provided below:
Market Capitalization
1.9 M
Earnings Share
(3.32)
We have found one hundred twenty available fundamental gauges for ZyVersa Therapeutics, which can be analyzed and compared to other ratios and to its peers. All investors should make sure to confirm all of ZyVersa Therapeutics prevalent market performance against the performance between 2010 and 2026 to make sure the company can sustain itself down the road. As of February 25, 2026, Market Cap is expected to decline to about 1.3 M. The current year's Enterprise Value is expected to grow to about (387.1 K)
Check ZyVersa Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among ZyVersa Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 7.8 K, Interest Expense of 398.8 K or Selling General Administrative of 8.9 B, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 0.13. ZyVersa financial statements analysis is a perfect complement when working with ZyVersa Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with ZyVersa Stock
Check out the analysis of ZyVersa Therapeutics Correlation against competitors.
For information on how to trade ZyVersa Stock refer to our How to Trade ZyVersa Stock guide.

ZyVersa Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets35.9 M23.7 M13.5 M
Slightly volatile
Short and Long Term Debt Total7.4 K7.8 K3 M
Slightly volatile
Other Current Liabilities1.8 M1.7 M2.7 M
Slightly volatile
Total Current Liabilities11.2 M12.9 M8.8 M
Slightly volatile
Other Liabilities12.9 M12.3 M3.6 M
Slightly volatile
Current Deferred Revenue15 K15.2 K19 K
Slightly volatile
Accounts Payable6.2 M10.7 M4 M
Slightly volatile
Cash2.4 M1.8 M1 M
Slightly volatile
Non Current Assets Total33.1 M21.7 M12.3 M
Slightly volatile
Non Currrent Assets Other156.1 K212.1 K260.4 K
Slightly volatile
Long Term Debt1.3 M1.5 M1.7 M
Slightly volatile
Cash And Short Term Investments2.4 M1.8 M1 M
Slightly volatile
Common Stock Shares Outstanding1.3 M1.3 M259.4 K
Slightly volatile
Liabilities And Stockholders Equity35.9 M23.7 M13.5 M
Slightly volatile
Non Current Liabilities Total728.2 K766.5 K2.5 M
Pretty Stable
Other Current Assets241.3 K166.4 K209.4 K
Slightly volatile
Other Stockholder Equity91.5 M139.3 M59.2 M
Slightly volatile
Total Liabilities14.2 M13.9 M10.9 M
Slightly volatile
Property Plant And Equipment Gross80.6 K59.8 K60.4 K
Slightly volatile
Short and Long Term Debt6.2 M10.5 M4.5 M
Slightly volatile
Total Current Assets2.8 M2 M1.2 M
Slightly volatile
Capital Stock450290306
Slightly volatile
Short Term Debt7.4 K7.8 K1.9 M
Pretty Stable
Common Stock449289306
Slightly volatile
Property Plant Equipment66.6 K133.1 K58.5 K
Slightly volatile
Intangible Assets15.9 M16.8 M80.7 M
Slightly volatile
Short Term Investments1.2 B1.4 B1.5 B
Slightly volatile

ZyVersa Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization7.8 K6.2 K9.8 K
Slightly volatile
Interest Expense398.8 K242.9 K488.1 K
Slightly volatile
Selling General Administrative8.9 B8.5 B2.1 B
Slightly volatile
Other Operating Expenses12.5 M10.5 M11.7 M
Very volatile
Research Development2.1 B2 B356.2 M
Slightly volatile
Cost Of Revenue7.8 K6.2 K9.8 K
Slightly volatile
Total Operating Expenses12.5 M10.5 M11.7 M
Very volatile
Reconciled Depreciation7.6 K6.2 K9.7 K
Slightly volatile
Interest Income366411449
Slightly volatile
Selling And Marketing Expenses9 B10.1 B11 B
Slightly volatile

ZyVersa Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation603.3 K635 K3.1 M
Slightly volatile
Begin Period Cash Flow2.3 M3.6 M1.4 M
Slightly volatile
Depreciation7.7 K6.2 K9.8 K
Slightly volatile
Total Cash From Financing Activities5.2 M6.8 M4.8 M
Slightly volatile
End Period Cash Flow1.3 M1.8 M627.7 K
Slightly volatile
Change To Netincome3 M3.2 M3.9 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Average Payables3.2 M3.6 M3.9 M
Slightly volatile
Capex To Depreciation3.0E-44.0E-44.0E-4
Slightly volatile
Payables Turnover8.0E-49.0E-40.0035
Slightly volatile
Cash Per Share1.181.2418.3396
Pretty Stable
Days Payables Outstanding464.5 K442.4 K168.7 K
Slightly volatile
Income Quality0.760.720.4576
Slightly volatile
Intangibles To Total Assets0.991.040.9449
Very volatile
Current Ratio0.220.140.1278
Slightly volatile
Capex Per Share0.00.00.0
Slightly volatile
Interest Debt Per Share0.270.2874.1053
Slightly volatile
Debt To Assets4.0E-45.0E-44.0809
Slightly volatile
Days Of Payables Outstanding464.5 K442.4 K168.7 K
Slightly volatile
Ebt Per Ebit0.880.931.4251
Pretty Stable
Effective Tax Rate8.0E-48.0E-40.0436
Slightly volatile
Quick Ratio0.220.140.1278
Slightly volatile
Net Income Per E B T0.760.90.9326
Slightly volatile
Cash Ratio0.190.120.1031
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.520.90.435
Slightly volatile
Debt Ratio4.0E-45.0E-44.0809
Slightly volatile

ZyVersa Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap1.3 M1.4 M114.3 M
Slightly volatile

ZyVersa Fundamental Market Drivers

ZyVersa Upcoming Events

13th of February 2024
Upcoming Quarterly Report
View
10th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
13th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About ZyVersa Therapeutics Financial Statements

ZyVersa Therapeutics stakeholders use historical fundamental indicators, such as ZyVersa Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Although ZyVersa Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in ZyVersa Therapeutics' assets and liabilities are reflected in the revenues and expenses on ZyVersa Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in ZyVersa Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue15.2 K15 K
Cost Of Revenue6.2 K7.8 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
FSLYFastly Class A
MOBMobilicom Limited American
CMGChipotle Mexican Grill
When determining whether ZyVersa Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ZyVersa Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Zyversa Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Zyversa Therapeutics Stock:
How To Invest In ZyVersa
Details
Is ZyVersa Stock a good investment?
Details
What is ZyVersa Therapeutics' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of ZyVersa Therapeutics Correlation against competitors.
For information on how to trade ZyVersa Stock refer to our How to Trade ZyVersa Stock guide.
You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ZyVersa Therapeutics. Anticipated expansion of ZyVersa directly elevates investor willingness to pay premium valuations. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive ZyVersa Therapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share
(3.32)
Return On Assets
(0.46)
Return On Equity
(1.13)
Investors evaluate ZyVersa Therapeutics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating ZyVersa Therapeutics' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause ZyVersa Therapeutics' market price to deviate significantly from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Please note, there is a significant difference between ZyVersa Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if ZyVersa Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Conversely, ZyVersa Therapeutics' market price signifies the transaction level at which participants voluntarily complete trades.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY